The Latest Breaking News from Oncology

  Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

Unlike their city counterparts, having access to essential cancer treatments is merely a dream for many on the NSW far south coast. And despite political promises, some fear that dream may never become a reality.

 

VIJAYAWADA

RBC Capital Market views Gilead Sciences Inc's (NASDAQ:GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses.  The analyst notes that the story remains somewhat catalyst light, especially with transformative M&A likely off the table.  HIV sales,…

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

AstraZeneca Plc's (NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete the delivery by half year 2022. Core EPS came in at $1.89,…

  During Thursday, 849 stocks hit new 52-week lows.

Merck & Co Inc's (NYSE:MRK) Q1 sales reached $15.90 billion, +50% Y/Y, beating the consensus of $14.68 billion. Excluding the foreign exchange impact, revenues were up 52%. Pharmaceutical sales increased 53% to $14.11 billion, primarily driven by molnupiravir, oncology, vaccines, and hospital acute care products.  Pharmaceutical sales growth, excluding Lagevrio sales, was…

MIAMI -- Caring for very sick children daily can be emotionally taxing, even for professionals with years of experience. As front-line workers who also support grieving parents, nurses often cope with chronic stress.

Stephens & Co. has decided to maintain its Equal-Weight rating of Universal Health Services (NYSE:UHS) and lower its price target from $150.00 to $135.00. Shares of Universal Health Services are trading down 0.72% over the last 24 hours, at $124.42 per share.